GH Research PLC Ordinary Shares (GHRS)
Stock · NASDAQ · Health Care
$18.17as of 10/16/2026
Price chart
Active signals
GHRS Signal Track Record
How signals performed across all stocks →What GHRS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | +2.7% | 55% | September 17, 2026 |
| Bollinger Band Breakout | 31 | -0.8% | 48% | August 6, 2026 |
| Bollinger Band Breakdown | 15 | +4.3% | 53% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +9.2% | 67% | October 7, 2026 |
| Any 20-session window (baseline) | +1.8% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GHRS
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpar…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 73
- Website
- www.ghres.com
Fundamentals
- 1-day range
- $18.48$19.39
- Market cap
- $2.10B
- P/E (trailing)
- —
- P/E (forward)
- -10.17
- EPS (trailing)
- $-0.99
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 284.0K
Forecasts
9 analyst ratings
GH Research PLC Ordinary Shares Competitors
Chosen by industry and closest market cap.
- GHRSGH Research PLC Ordinary Shares$18.15▼ 3.51%Market cap $2.10BP/E —$12.04$31.44
- AUPHAurinia Pharmaceuticals Inc Ordinary Shares$16.51▼ 1.31%Market cap $2.10BP/E 7.11$11.21$19.25
- NUVBNuvation Bio Inc. Class A Common Stock$4.45▼ 6.32%Market cap $2.13BP/E —$3.36$9.75
- HCMHUTCHMED (China) Limited American Depositary Shares$14.05▲ 0.79%Market cap $2.06BP/E 133.15$15.57$26
- STOKStoke Therapeutics Inc. Common Stock$24.17▼ 1.79%Market cap $2.06BP/E —$20.32$40.22
- ZBIOZenas BioPharma Inc. Common Stock$24.84▼ 2.20%Market cap $2.03BP/E —$13.5$44.6
- BHVNBiohaven Ltd. Common Shares$10.78▼ 5.69%Market cap $2.17BP/E —$7.48$18.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GHRS GH Research PLC Ordinary Shares | $2.10B | — | $18.15 | ▼ 3.51% | $12.04$31.44 |
| AUPH Aurinia Pharmaceuticals Inc Ordinary Shares | $2.10B | 7.11 | $16.51 | ▼ 1.31% | $11.21$19.25 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.13B | — | $4.45 | ▼ 6.32% | $3.36$9.75 |
| HCM HUTCHMED (China) Limited American Depositary Shares | $2.06B | 133.15 | $14.05 | ▲ 0.79% | $15.57$26 |
| STOK Stoke Therapeutics Inc. Common Stock | $2.06B | — | $24.17 | ▼ 1.79% | $20.32$40.22 |
| ZBIO Zenas BioPharma Inc. Common Stock | $2.03B | — | $24.84 | ▼ 2.20% | $13.5$44.6 |
| BHVN Biohaven Ltd. Common Shares | $2.17B | — | $10.78 | ▼ 5.69% | $7.48$18.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion OpportunitiesSeekingAlpha · 9/20/2026
Insider Activity
Insider Actions →- Schonharting Florian · September 8, 2026 · Grant2.3K
- Moore Duncan · August 11, 2026 · Grant2.2K
- Hanley Dermot John · August 11, 2026 · Grant2.2K
- Forer Michael · August 11, 2026 · Grant100.0K
- Forer Michael · August 11, 2026 · Grant2.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
GHRS: Advancement Presses On, Expansion Opportunities Highlighted
A SeekingAlpha article noted that GH Research’s advancement efforts are continuing and that the company has identified new expansion opportunities. The piece suggests the firm is positioning itself for further growth in its market. This comes while the stock’s RSI is in the mid‑30s, indicating modest recent price momentum.
GHRS: Advancement Presses On, Expansion Opportunities Highlighted. A SeekingAlpha article noted that GH Research’s advancement efforts are continuing and that the company has identified new expansion opportunities. The piece suggests the firm is positioning itself for further growth in its market. This comes while the stock’s RSI is in the mid‑30s, indicating modest recent price momentum.